左旋门冬酰胺酶在儿童急性淋巴细胞白血病临床应用的安全性分析  

Clinic application and safety analysis of L-asparaginase in treatment of children with acute lymphocytic leukemia

作　　者：王艳春[1] 陶蕾[1] 

机构地区：[1]航空总医院药剂科,北京100012

出　　处：《药物评价研究》2012年第4期285-288,共4页Drug Evaluation Research

摘　　要：左旋门冬酰胺酶(L-ASP)作为儿童急性淋巴细胞白血病治疗联合化疗方案中的最基本药物之一,在对维持患儿长期处于带病生存状态中起着极为重要的作用。但长期以来其在儿童临床应用的安全性也一直是人们关注的重点。就近些年L-ASP在国内外儿童临床应用引起不良反应的类型、原因以及发展方向等方面的研究进展进行综述。L-asparaginase（L-ASP）,one of the most basic drugs in the treatment of acute lymphocytic leukemia（ALL） for children,has played an extremely important role for maintaining the long-term event-free survival rates in ALLfor children.However,the side effects caused by L-ASP have also been concerned.In this paper,the progress in studies on types and reasons of the side effects of L-ASP in the treatment of ALL for children and its development direction are reviewed.

关 键 词：左旋门冬酰胺酶 急性淋巴细胞白血病 不良反应 儿童用药 

分 类 号：R979.1[医药卫生—药品]